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Introduction
Mosaic-variegated aneuploidy (MVA) syndrome is an autosomal 
recessive syndrome characterized by near-diploid aneuploidies 
involving multiple tissues and chromosomes (1–4). A wide variety 
of additional clinical features are associated with this syndrome, 
including microcephaly, growth and mental retardation, hypo-
thyroidism, facial dysmorphisms, skeletal and renal anomalies, 
gastrointestinal and cardiac defects, childhood cancers, and early 
mortality (5). Three genes, all with roles in chromosome segrega-
tion, have been implicated in MVA syndrome: the mitotic check-
point gene BUBR1 (also named BUB1B) (1, 2, 5), the centrosomal 
protein CEP57 (3, 6), and the spindle assembly checkpoint (SAC) 
activator TRIP13 (4). The majority of patients have bi- or monoal-
lelic mutations in BUBR1, with biallelic alterations typically involv-
ing a nonsense mutation in combination with a missense mutation 
in the kinase domain of the protein (2, 5). Patients with monoallel-
ic mutations inherit a nonsense or missense mutation in combi-
nation with a hypomorphic allele, without a clear mutation, that 
yields low amounts of wild-type BUBR1 protein (1, 5).
Phenotypic variability is remarkably high among MVA syn-
drome patients, not only between patients that have mutations 
in different MVA genes, but also between those with distinct 
mutations in the same gene (2–5). Although MVA cases with 
BUBR1 mutations constitute the largest cohort, the overall size of 
this group is still too small for meaningful genotype-phenotype 
correlation analyses. One distinguishing feature observed in all 
MVA patients, regardless of the underlying mutations, is that they 
inaccurately segregate whole chromosomes, which has prompted 
speculation that the resulting aneuploidies drive the clinical fea-
tures of the syndrome (7). However, decisive evidence to support 
this idea remains elusive. For instance, genetically engineered 
mice with alterations in chromosomal instability (CIN) genes 
are often predisposed to tumors, but do not exhibit other clinical 
phenotypes of MVA syndrome, with the exception of one BubR1-
based aneuploid model (8).
This particular model was part of a series of mouse mutants 
with a graded reduction in BUBR1 protein levels created by the use 
of wild-type (+), hypomorphic (H), and knockout (–) BubR1 alleles. 
Mutants expressing 0% (BubR1–/–) or approximately 5% (BubR1–/H) 
of normal BUBR1 protein levels fail to survive beyond embryonic 
day 3.5 (E3.5) and postnatal day 1, respectively, but mice express-
ing approximately 10% BUBR1 (BubR1H/H) are viable (8). Besides 
near-diploid aneuploidies, these mice exhibit growth retardation, 
facial dysmorphisms, skeletomuscular, renal, and cardiac anoma-
lies, cataracts, lipodystrophy, and early mortality (8–11). Further-
more, BubR1H/H mice are sensitive to carcinogen-induced tumors, 
but do not live long enough to assess predisposition to spontaneous 
tumors (12). Several of the progeroid phenotypes in BubR1H/H mice 
are driven by the accumulation of senescent cells (9–11), which in 
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Results
Mice modeling MVA patient BUBR1X753/L1012P die during early embryo-
genesis. BUBR1 2211insGTTA, a mutant BUBR1 allele that results 
in a frameshift and yields an unstable truncated protein referred 
to as BUBR1X753, has been identified in 2 biallelic MVA patients, 
one of which also inherits BUBR1 3035T>C, a mutant allele that 
encodes BUBR1L1012P (2). To model this particular patient, we used 
a previously established mouse strain in which we mimicked the 
BUBR1 2211insGTTA allele (21) and a new strain in which we con-
verted the leucine at position 1002 into a proline (human L1012 
corresponds to mouse L1002; Figure 1A and Supplemental Figure 
1, A–C; supplemental material available online with this article; 
https://doi.org/10.1172/JCI126863DS1). As expected, heterozy-
gotes carrying the L1002P substitution (referred to as BubR1+/L1002P 
mice) were overtly normal. However, mouse embryonic fibro-
blasts (MEFs) and tissues from BubR1+/L1002P mice contained mark-
edly reduced BUBR1 levels (Figure 1B). Side-by-side comparisons 
of BubR1+/L1002P, BubR1+/–, and BubR1+/X753 MEFs and tissues implied 
that the BubR1L1002P allele overall yields very little protein (Figure 
1B). However, MEFs and testes from BubR1+/– and BubR1+/X753 mice 
had significantly lower BUBR1 protein levels than corresponding 
tissues from BubR1+/L1002P mice, whereas levels were similarly low 
in the thymus and spleen of all 3 genotypes. The L1002P muta-
tion had no impact on BubR1 transcript stability, but the truncat-
ing X753 mutation did, with BubR1+/X753 MEFs yielding transcript 
levels similar to those of BubR1+/– MEFs (Supplemental Figure 2A). 
Assessments of BUBR1 protein stability revealed that proteasomal 
degradation of BUBR1L1002P was elevated (Supplemental Figure 2, 
B and C), which is in concordance with an earlier study showing 
that human BUBR1L1012P protein is misfolded and therefore less 
stable (7). Nevertheless, mitotic BubR1+/L1002P MEFs were still able 
to accumulate normal amounts of BUBR1 at unattached kineto-
chores, as demonstrated by immunofluorescence (IF) labeling for 
BUBR1 (Supplemental Figure 2F). BUBR1WT protein stability in 
BubR1+/X753 MEFs seemed similar to that in BubR1+/+ and BubR1+/– 
MEFs (Supplemental Figure 2, C–E).
To model the MVA patient BUBR1X753/L1012P, we intercrossed 
BubR1+/L1002P and BubR1+/X753 mice, but no BubR1X753/L1002P mice 
were identified among 388 newborn pups (Supplemental Table 
1). This was unexpected because the patient with this genetic 
combination was alive for 3.6 months after birth, despite growth 
retardation and anomalies in a broad spectrum of tissues, 
including heart, lung, brain, eye, thyroid, and erythrocytes (2). 
To determine when BubR1X753/L1002P mice die during embryogen-
esis, we genotyped a total of 39 E13.5 mice from heterozygous 
intercrosses, but again no BubR1X753/L1002P mice were observed, 
whereas BubR1+/L1002P, BubR1+/X753, and BubR1+/+ mice were pres-
ent at expected frequencies (Supplemental Table 1). Howev-
er, repeating the analysis at E3.5 yielded viable BubR1X753/L1002P 
embryos, which were overtly indistinguishable from their 
BubR1+/L1002P, BubR1+/X753, and BubR1+/+ counterparts (Supple-
mental Table 1). Attempts to culture the inner cell mass from 
BubR1X753/L1002P blastocysts were unsuccessful; however, this was 
indicative of early embryonic death due to mitotic failure (data 
not shown). Thus, a mouse model for MVA patient BUBR1X753/L1012P 
is unattainable, most likely due to severe mitotic defects that 
interfere with early embryogenesis.
turn led to the identification of cellular senescence as a key con-
tributor to natural aging (13).
Two additional observations have reinforced a possible role 
for BUBR1 in aspects of natural aging. First, BUBR1 levels decline 
in various tissues with chronological aging, with geriatric wild-
type mice expressing similar amounts of the protein to those of 
young BubR1H/H mice (8). Second, transgenic mice that constitu-
tively overexpress BUBR1 are not subject to an age-related decline 
in BUBR1 and have an increased lifespan with attenuations in 
muscle and renal atrophy, glomerulosclerosis, cardiac aging, 
and tumor latency (14). BUBR1 overexpression was also shown to 
counteract age-related aneuploidization in various tissues, raising 
the possibility that inaccurate chromosome segregation may be a 
driver of tissue deterioration with aging. BUBR1 overexpression 
appears to reinforce both the spindle assembly checkpoint (SAC) 
and the mitotic error correction machinery, which may underlie 
the observed reductions in aneuploidization rates (15).
The high clinical heterogeneity among MVA patients with 
BUBR1 mutations has prompted the idea that BUBR1 is a multi-
tasking protein implicated in a wide variety of biological processes 
that are differently disrupted, depending on the exact nature of 
the mutations involved. Early in mitosis, BUBR1, together with 
MAD2, BUB3, and CDC20, assembles into a potent 4-subunit 
inhibitor (known as the mitotic checkpoint complex, MCC) of the 
anaphase-promoting complex (APC/C) that prevents premature 
anaphase and chromosome missegregation as part of the SAC (16, 
17). Once each chromosome has properly and stably attached to 
the mitotic spindle and sufficient inter-kinetochore tension is gen-
erated, the MCC dissociates, allowing APC/CCDC20 to mediate the 
proteasomal degradation of cyclin B1 and securin, thereby trigger-
ing sister chromatid separation and anaphase onset. BUBR1 also 
prevents chromosome missegregation as a key component of the 
Aurora B–driven error correction machinery, which acts to destabi-
lize aberrant microtubule-kinetochore attachments, and through 
the reactivation of the SAC allows time for proper attachments 
to occur (18). In this context, BUBR1 localized at mitotic kineto-
chores acts to recruit PP2A, the phosphatase that counteracts the 
destabilizing activity of Aurora B kinase (19). Furthermore, BUBR1 
regulates clathrin-mediated internalization of the insulin recep-
tor by virtue of its ability to bind to both MAD2 and AP2, thereby 
quenching signaling through this receptor (20). BUBR1 fulfils this 
newly discovered function in interphase, further supporting the 
idea that BUBR1 is a functionally diverse protein with a plethora of 
mitotic and non-mitotic roles.
Despite significant progress toward understanding these con-
tributions of BUBR1, it remains unclear what the full spectrum of 
physiologically relevant functions of this protein are, the extent 
to which the various BUBR1 mutations might perturb these func-
tions, and how all this contributes to the vast clinical heteroge-
neity within MVA syndrome. To begin to address some of these 
unresolved questions, we sought to mimic human BUBR1 MVA 
mutations in mice and characterize the phenotypic consequences. 
Here, our use of 4 such mutations in various combinations with 
each other or in combination with a BubR1+ allele demonstrates 
that subtle allelic effects contribute to disease heterogeneity in 
both MVA patients and heterozygous carriers of MVA mutations, 
beyond rates of aneuploidy and BUBR1 protein levels.
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BubR1+/– mice. Consistent with earlier data (21), BubR1+/– mice had 
a modest, but significant, reduction in lifespan compared with 
BubR1+/+ mice (Figure 2A). BubR1+/L1002P mice also showed a strong 
trend toward reduced median lifespan that was close to reaching 
significance (P = 0.0516, log-rank test). Although in both heterozy-
gous mutant cohorts the incidence and spectrum of spontaneous 
tumors detectable at autopsy were similar to wild-type (Figure 
2, B and C), tumor latencies in both mutants were significantly 
reduced (Figure 2A), indicating that both MVA mutations may 
promote tumorigenesis by accelerating tumor growth. Consistent 
with this, lymphomas from BubR1+/L1002P and BubR1+/– mice, which 
developed with reduced latencies, contained significantly more 
mitotic cells than lymphomas of BubR1+/+ mice (Figure 2, D and 
E). A complementary experiment in which we analyzed tumor-
Models for heterozygous BUBR1 MVA mutations show phenotyp-
ic heterogeneity. Whether heterozygous carriers of BUBR1 MVA 
mutations might develop any symptoms associated with the syn-
drome is a key question that remains to be addressed. In a previous 
study, we examined mice that model an MVA allele carrier, het-
erozygous for the BUBR1X753 mutation, and found that these mice 
were indeed more susceptible to cancer and select progeroid phe-
notypes than their wild-type counterparts (21). To develop a more 
comprehensive understanding of the impact of heterozygous MVA 
mutations, we modeled heterozygous carriers of 2 other MVA 
alleles, BUBR1L1012P and BUBR1–, the latter representing the null 
allele found in a biallelic MVA patient that also carries a BUBR1I909T 
mutation (2). The necessary cohorts of BubR1+/+, BubR1+/L1002P, and 
BubR1+/– mice were established by intercrossing BubR1+/L1002P and 
Figure 1. MVA alleles BUBR1L1012P and BUBR1X753 
yield low amounts of protein. (A) Schematic 
of BUBR1 protein. Locations of MVA patient 
mutations are indicated. Ken, Ken box; Tpr, 
tetratricopeptide repeat motif; D-box, destruction 
box; Glebs, Glebs-binding motif; Phe, Phe box; 
Kard, kinetochore attachment regulatory domain; 
Kinase, kinase domain. (B) Western blots of asyn-
chronous passage-5 MEF and proliferative tissue 
lysates (6-week-old mice) probed for BUBR1. Total 
protein (Ponceau S [PonS] staining) and α-tubulin 
served as independent loading controls. BUBR1 
levels were quantified and normalized to α-tubu-
lin or PonS. Numerical values indicate quantified 
BUBR1 levels, with BubR1+/+ normalized to 1. 
Values below the horizontal lines represent the 
mean. Statistical significance was determined 
using 1-way ANOVA with the Holm-Šídák post 
hoc test (B). *P < 0.05; **P < 0.01; ***P < 0.001. 
NS, not significant.
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Figure 2. Carriers of single BUBR1 MVA mutations are phenotypically heterogeneous. (A) Kaplan-Meier curves showing overall survival (left) and cancer 
deaths only (right) of the indicated mice. Values associated with curves denote median survival. (B) Incidence of cancer deaths in the indicated mice. (C) 
Spectrum of cancer types associated with cancer deaths in the indicated mice. (D) Kaplan-Meier curve for lymphoma deaths of the indicated mice. Median 
survival is indicated. (E) Mitotic index of the lymphoma tumor samples collected from the indicated moribund mice. Images of representative pHH3- 
labeled lymphoma sections are shown. Scale bar: 50 μm. (F and G) DMBA-induced lung tumor incidence, multiplicity, and volume in the indicated mice. 
Bars in E–G represent the mean ± SEM, and dots represent individual samples. Each n for all experiments represents individual mice, with the exception 
of tumor volume in F–G where individual tumors are represented. Statistical significance was determined using a log-rank test (A and D), 2-tailed Fisher’s 
exact test (B–C and F–G, incidence), 1-way ANOVA with the Holm-Šídák post hoc test (E), and a Mann–Whitney U test (F–G, tumor number and volume). 
*P < 0.05; **P < 0.01; ***P < 0.001. NS, not significant.
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BubR1+/X753 MEFs compared with BubR1+/+ MEFs (Figure 3A and 
Supplemental Table 2). Premature chromatid separation (PCS), 
a hallmark of MVA patients, was observed in all 3 MVA allele 
carriers (Figure 3A). We complemented these experiments with 
interphase fluorescence in situ hybridization (FISH) analyses for 
chromosomes 4 and 7 in these MEFs, which targets the entire cell 
population rather than only the mitotically active fraction. Aneu-
ploidy rates were again similarly increased in all 3 MVA allele car-
riers (Supplemental Figure 5 and Supplemental Table 3).
By monitoring chromosome movements during mitosis in 
live cells expressing histone H2B–monomeric red fluorescent pro-
tein (H2B-mRFP), we observed small, but significant increases in 
chromosome segregation errors for all 3 heterozygous BubR1 MVA 
mutants (Figure 3B). In all 3 heterozygous mutants both the SAC 
and attachment error correction machinery were impaired, provid-
ing an explanation for the observed increase in segregation errors 
(Figure 3, C and D). However, both high-fidelity chromosome seg-
regation insurance systems were similarly impaired in all 3 mutants, 
prompting us to screen for additional mitotic defects that might 
explain the higher rates of lagging chromosomes in BubR1+/L1002P 
and BubR1+/X753 MEFs (Figure 3B). Lagging chromosomes are fre-
quently caused by aberrancies in centrosome disjunction or move-
ment that result in the formation of non-perpendicular spindles that 
are enriched in merotelic kinetochore-microtubule attachments 
igenesis by performing a timed sacrifice at 18–20 months of age 
confirmed that the incidence of tumor formation and the spec-
trum of tumors in BubR1+/L1002P and BubR1+/– mice were unchanged 
(Supplemental Figure 3, A and B).
To extend our cancer susceptibility studies, we challenged 
BubR1+/+, BubR1+/L1002P, and BubR1+/– mice with 7,12-dimethylbenz(a)
anthracene (DMBA), a carcinogen that primarily induces lung 
tumors when applied on the dorsal skin at postnatal day 5 (22). Both 
BubR1+/L1002P and BubR1+/– mice showed no increase in lung tumor 
incidence in this tumor bioassay. Lung tumor multiplicity and size, 
however, were significantly increased in BubR1+/– mice, and likewise 
lung tumor size was also increased in BubR1+/L1002P mice, indicative 
of accelerated tumor growth and/or initiation (Figure 2, F and G). 
Thus, together with earlier studies in BubR1+/X753 mice, these find-
ings imply that heterozygous carriers of BUBR1 MVA mutations may 
be at increased risk of tumor formation, albeit to different degrees. 
In contrast with BubR1+/X753 mice (21), BubR1+/– and BubR1+/L1002P 
mice showed little to no evidence of accelerated aging phenotypes 
(Supplemental Figure 4, A–E).
Heterozygous BUBR1 MVA mutants demonstrate intricate mitotic 
phenotypes. To examine the impact of heterozygous BUBR1 MVA 
mutations on chromosome number integrity, we performed chro-
mosome counts on metaphase spreads of MEFs at passage-5. 
Aneuploidy was markedly elevated in BubR1+/L1002P, BubR1+/–, and 
Figure 3. Surveillance mechanisms that ensure high-fidelity chromosome segregation are defective in monoallelic BubR1 MVA mutant MEFs. (A) Inci-
dence of aneuploidy and PCS in mitotically arrested passage-5 MEFs. (B) Chromosome segregation errors in passage-5 MEFs assessed by live-cell imaging 
of MEFs expressing H2B-mRFP. Each n indicates independent MEF lines for all genotypes, except for BubR1+/L1002P and BubR1+/X753, where technical repli-
cates were performed on 4 and 3 independent lines, respectively. (C) Colcemid-challenge assay on passage-5 MEFs measuring SAC activity. (D) Error cor-
rection in the indicated passage-5 MEFs assessed by monastrol washout assay. Representative images are shown. Yellow arrowheads indicate misaligned 
chromosomes. (E and F) Incidence of slow centrosome movement (E) and non-perpendicular spindles (F) in the indicated passage-5 MEFs. Representative 
images are shown. Yellow arrowheads indicate the location of the centrosomes. Each n indicates independent MEF lines, unless otherwise noted. Data are 
presented as mean ± SD (A) and mean ± SEM (B–F), and dots represent individual samples. Scale bars: 3 μm (D and E) and 2 μm (F). Statistical significance 
was determined using 1-way ANOVA with the Holm-Šídák post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001. NS, not significant.
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(23, 24). Indeed, both monoallelic MVA mutants with increased 
chromosome lagging formed non-perpendicular spindles at ele-
vated rates, due to slow centrosome movement (Figure 3, E and F). 
Although it remains to be determined how BUBR1 impacts centro-
some movement, it is clear that there is an allele-dependent effect 
on this process. Overall, the above experiments indicate that allelic 
effects beyond BUBR1 levels alone contribute to the mitotic pheno-
types of monoallelic MVA mutants.
We complemented our analyses of cultured MEFs with 
chromosome counts on splenocytes of 5-month-old BubR1+/–, 
BubR1+/L1002P, and BubR1+/X753 mice. Specifically, we briefly cul-
tured freshly harvested splenocytes in the presence of colcemid 
for 4 hours prior to preparing metaphase spreads and counting 
chromosomes. This method assesses the percentage of aneu-
ploid cells among the subset of cycling splenocytes entering 
mitosis. We observed major differences in aneuploidy between 
heterozygous BubR1 MVA mutants, with 2%, 18%, and 28% of 
mitotic splenocytes showing abnormal chromosome numbers in 
BubR1+/–, BubR1+/X753, and BubR1+/L1002P mice, respectively (Figure 
4A and Supplemental Table 4). The same was true for PCS (Fig-
ure 4A). To investigate karyotypic instability in greater depth, we 
conducted interphase FISH analysis for chromosomes 4 and 7 
on liver, lung, and spleen of BubR1+/+, BubR1+/–, BubR1+/L1002P, and 
BubR1+/X753 mice ranging in age from 22–24 months. Instead of tis-
sue sections, we prepared single-cell suspensions from the above 
tissues and dropped these on slides to avoid the loss of nuclear 
content that occurs with sectioning (14). Our analyses showed 
that aneuploidy was increased in livers of BubR1+/L1002P and 
BubR1+/– mice, as well as in lungs of BubR1+/L1002P and BubR1+/X753 
mice (Figure 4B and Supplemental Table 3). Aneuploidy rates in 
the spleen, as measured by FISH, were not elevated in any of the 
monoallelic MVA mutants, even though substantial increases 
were observed in mitotically active splenocytes of these strains 
(Figure 4, A and B). One possible explanation might be that chromo-
some missegregation or aneuploid cell survival rates differentially 
change over time for each of the mutants. Notwithstanding these 
differences, collectively, these data suggest that a key feature of 
MVA syndrome patients, increased aneuploidy in multiple tissues, 
is conserved in heterozygous carriers of BUBR1 MVA mutations.
Progeroid BubR1+/X753 mice exhibit hyperactive mTORC1 sig-
naling. To further investigate the basis for the phenotypic het-
erogeneity among monoallelic MVA mutants, we conducted 
genome-wide transcriptome profiling on gastrocnemius muscle 
from 3-month-old BubR1+/X753, BubR1+/L1002P, and BubR1+/+ mice. 
This tissue was chosen because in BubR1+/X753 mice it is selective-
ly subject to accelerated aging (21). The 3-month time point was 
selected because at this age no signs of muscle aging are detected, 
allowing for detection of primary alterations resulting from the 
presence of the BubR1X753 allele rather than secondary transcrip-
tional changes associated with sarcopenia. Strikingly, several hun-
dred differentially expressed genes (DEGs) emerged when com-
paring BubR1+/X753 with BubR1+/+, whereas the transcriptome of 
BubR1+/L1002P skeletal muscle was similar to that of BubR1+/+, yield-
ing only 3 DEGs (Figure 5A). Comparison of BubR1+/X753 with 
BubR1+/L1002P also yielded a significant number of DEGs, albe-
it fewer than compared with BubR1+/+ (Figure 5A). Functional 
enrichment analyses with the DEGs using the STRING database 
(25) revealed that the majority of cellular functions that were sig-
nificantly enriched in the upregulated DEGs of BubR1+/X753 skel-
etal muscle were linked to the mTORC1 signaling pathway (Fig-
ure 5B), which has been linked to aging (26). In addition, a high 
percentage of the upregulated DEGs from the BubR1+/X753 versus 
BubR1+/L1002P comparison function in mTORC1-related biological 
processes (Supplemental Figure 6, A and B). Consistent with this, 
phosphorylation of 2 key mTORC1 substrates, p70 S6 kinase and 
4EBP1, were markedly increased in skeletal muscle of 3-month-
Figure 4. Monoallelic BubR1 MVA mutants exhibit mosaic aneuploidies. (A) Incidence of aneuploidy and PCS in mitotic splenocytes of 5-month-old mice. (B) 
Incidence of aneuploidy in tissues from 22- to 24-month-old mice assessed by FISH for chromosomes 4 and 7. Representative images are shown. Each n indi-
cates cells or tissues from independent mice. Data are presented as mean ± SD (A) and mean ± SEM (B), and dots represent individual samples. Scale bar: 2 μm 
(B). Statistical significance was determined using 1-way ANOVA with the Holm-Šídák post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001. NS, not significant.
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old BubR1+/X753 mice compared with corresponding lysates from 
BubR1+/L1002P and BubR1+/+ mice, as determined by Western blot 
analysis (Figure 5C). Skeletal muscle from BubR1+/L1002P and 
BubR1+/X753 mice had similarly reduced BUBR1 protein levels com-
pared with BubR1+/+ mice, indicating that differences in BUBR1 
protein levels are unlikely to account for the differential impact of 
these MVA mutations on mTORC1 signaling (Figure 5D). The pos-
sibility that BUBR1 levels initially decline similarly in BubR1+/L1002P 
and BubR1+/X753 young adult mouse tissues, but then more rap-
idly in BubR1+/X753 mice as animals reach a more advanced age is 
also unlikely, as suggested by Western blot analysis for BUBR1 on 
spleen lysates of 24-month-old mice (Supplemental Figure 7).
BubR1H/L1002P mice are viable and model MVA syndrome–associ-
ated pathologies. Following our unsuccessful attempt to model the 
BUBR1X753/L1012P MVA patient in mice, we asked whether the BubR1H 
allele, which mimics the hypomorphic allele found in patients with 
monoallelic BUBR1 mutations (1, 8), might produce viable offspring 
when combined with BubR1X753 or BubR1L1002P. Indeed, intercross-
es of BubR1+/X753 and BubR1+/H mice yielded viable BubR1H/X753 off-
spring; however, these mice failed to thrive and died within 18 hours 
after birth (Figure 6A), reminiscent of BubR1–/H mice (8). Compara-
tive Western blot analysis of MEF lysates revealed that BubR1–/H and 
BubR1H/X753 MEFs had a similar reduction in BUBR1 protein (Figure 
6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H 
mice yielded BubR1H/L1002P mice that had a normal appearance at 
birth, but became growth retarded during postnatal development, 
although not as severely as BubR1H/H mice (Figure 6, C and D). 
Although postnatal viability of BubR1H/X753 and BubR1H/L1002P mice 
was markedly different, residual BUBR1 protein levels in MEFs of 
these genotypes were not significantly different from each other 
(Supplemental Figure 8A). Furthermore, despite the significant 
differences in body size between BubR1H/L1002P and BubR1H/H mice, 
the level of BUBR1 protein reduction in MEFs and multiple tissues 
appeared to be very similar between the mutants, with significant 
Figure 5. Progeroid BubR1+/X753 mice exhibit aberrant cellular signaling. (A) Venn diagrams of DEGs from RNA sequencing analyses of gastrocnemius 
muscle from 3-month-old mice of the indicated genotypes. ↑, upregulated genes; ↓, downregulated genes. n = 3 independent mice/genotype. (B) Func-
tional enrichment analyses on the 336 BubR1+/X753 versus BubR1+/+ upregulated DEGs. Biological processes clustered by common function. Significantly 
enriched (FDR < 0.05, –log10 > 1.3) processes are shown. Bars represent maximum –log10(FDR) per functional group, and dots represent individual annota-
tions for pathways under a given functional group. Numbers above bars represent the total number of pathways per group. (C) Western blot of gastrocne-
mius muscle from two 3-month-old mice of the indicated genotypes. PonS served as the loading control. (D) Western blot of gastrocnemius muscle from 
three 10-day-old mice of the indicated genotypes, probed for BUBR1. PonS served as the loading control. BUBR1 levels were quantified and are shown as in 
Figure 1B. See Methods for statistical analyses for RNA sequencing and functional enrichment analyses (A and B). Statistical significance was determined 
using 1-way ANOVA with the Holm-Šídák post hoc test (D). ***P < 0.001. NS, not significant.
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Figure 6. Mouse models carrying 2 allelic BubR1 MVA patient variants are viable. (A) Image of BubR1+/+ and BubR1H/X753 pups a few hours after birth. 
(B) Western blots of asynchronous passage-5 MEF lysates, probed for BUBR1. PonS-stained proteins served as the loading control. Three independent 
lines were used for analyses. BUBR1 levels were quantified and are shown as in Figure 1B. (C) Representative image of 8- to 10-month-old mice. Dashed 
yellow line outlines curvature of the spine, indicating kyphosis phenotype in BubR1H/L1002P and BubR1H/H mice. (D) Mean weights of BubR1+/+, BubR1H/L1002P, 
and BubR1H/H mice at 5–7 months of age. Each n indicates independent mice. (E) Western blots of tissues from 6-week-old (testes, thymus, and spleen) 
and 10-day-old (gastrocnemius muscle and fat) mice, and passage-5 asynchronous MEFs of the indicated genotypes. PonS served as the loading control. 
BUBR1 levels were quantified and are shown as in Figure 1B. (F) Survival curves for the indicated mouse models. Values associated with curves denote 
median survival. P < 0.05 for BubR1H/H versus BubR1H/L1002P. (G) DMBA-induced lung tumor incidence, multiplicity, and volume in the indicated mice. Data 
in D and G are presented as the mean ± SEM, and dots represent individual samples. Statistical significance was determined using 1-way ANOVA with the 
Holm-Šídák post hoc test (B, D, and E), log-rank test (F), 2-tailed Fisher’s exact test (G, incidence), and Mann–Whitney U test (D and G, tumor number and 
volume). *P < 0.05; **P < 0.01; ***P < 0.001. NS, not significant.
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multiplicity of DMBA-induced lung tumors were significantly 
elevated (Figure 6G), analogous to BubR1H/H mice (12). Howev-
er, the average lung tumor size was increased in DMBA-treated 
BubR1H/L1002P mice compared with corresponding BubR1+/+ mice 
(Figure 6G). This was not observed in BubR1H/H mice (12) and is 
perhaps a feature of select MVA alleles, as this was also noted in 
a milder form in BubR1+/L1002P, BubR1+/–, and BubR1+/X753 mice (Fig-
ure 2, F and G, and ref. 21).
differences observed only in the spleen (Figure 6E). BubR1H/L1002P 
mice had a median lifespan of 343 days compared with 691 days for 
BubR1+/+ mice (Figure 6F). Although BubR1H/L1002P mice were short-
lived, on average they lived significantly longer than BubR1H/H mice, 
which had a median lifespan of 196 days (Figure 6F).
Similar to BubR1H/H mice, BubR1H/L1002P mice were not prone 
to spontaneous tumors, with only 13% of mice dying with mac-
roscopically detectable tumors. Furthermore, the incidence and 
Figure 7. BubR1H/L1002P and BubR1H/H mice recapitulate MVA syndrome heterogeneity. (A) Kaplan-Meier curves of cataract onset in the indicated mice. 
Values associated with curves denote median onset. Representative images of 5-month-old mice are shown in insets. (B) Kaplan-Meier curves of kyphosis 
onset in the indicated mice. Values associated with curves denote median onset. P < 0.001 for BubR1H/H versus BubR1H/L1002P. (C) Analysis of forelimb grip 
strength in the indicated 5- to 7-month-old mice. (D) Histological analyses of gastrocnemius and measurement of muscle fiber cross-sectional area in the 
indicated 8- to 10-month-old mice. Representative images shown. Scale bar: 50 μm. (E) Mean work output, in joules (J), during a treadmill exercise test of 
5- to 7-month-old mice. (F) Mean total body fat percentage of 8- to 10-month-old mice, as determined by echo-MRI analyses. (G) Histological analyses of 
inguinal adipose tissue (IAT) and measurement of adipocyte cross-sectional area in the indicated 8- to 10-month-old mice. Representative images shown. 
Scale bar: 50 μm. (H) Survival curves of the indicated 4- to 7-month-old mice exposed to a low-dose isoproterenol regimen to evaluate cardiac stress toler-
ance. Each n indicates independent mice for all experiments. Data in C–G are presented as mean ± SEM, and dots represent individual samples. Statistical 
significance was determined using a log-rank test (A, B, and H) and 1-way ANOVA with the Holm-Šídák post hoc test (C–G). *P < 0.05; **P < 0.01;  
***P < 0.001. NS, not significant.
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ples. Although attempts to model MVA patient mutations in mice 
have proven difficult (Supplemental Table 1 and ref. 6), a system-
atic analysis of the mitotic phenotypes of the currently available 
models is likely to provide valuable insight into the extent to which 
mitosis-related abnormalities might contribute to the pathological 
heterogeneity. To do so, we subjected BubR1H/X753, BubR1H/L1002P, 
and BubR1H/H MEFs and multiple tissues from BubR1H/L1002P and 
BubR1H/H adult mice to the same mitotic and karyotypic tests that 
we conducted on mice modeling heterozygous BUBR1 MVA muta-
tions (Figures 3 and 4).
We detected exceptionally high rates of both aneuploidy and 
PCS in passage-5 BubR1H/X753 MEFs (Figure 8A and Supplemental 
Table 2), similar to earlier data on BubR1–/H MEFs (65% versus 
72% aneuploidy, respectively) (8). This is in accordance with the 
fact that BubR1H/X753 and BubR1–/H mice both die shortly after birth 
and express similar BUBR1 levels in MEFs (Figure 6, A and B). 
Aneuploidy rates were also relatively high in BubR1H/L1002P MEFs, 
reaching virtually the same levels as observed in BubR1H/H MEFs 
(Figure 8A and Supplemental Table 2). The only notable differ-
ence between the 2 genotypes was the dramatic difference in PCS 
(Figure 8A), indicating that the presence of BUBR1L1002P protein 
interferes with the cell’s ability to sustain strong bonds between 
duplicated chromosomes before anaphase onset. To examine the 
aneuploidy phenotypes of these biallelic MVA mutants in greater 
depth, we performed single-cell DNA sequencing on asynchro-
nously growing passage-5 BubR1+/+, BubR1H/L1002P, BubR1H/H, and 
BubR1H/X753 MEFs. In this analysis, nearly all BubR1H/X753 MEFs 
exhibited whole-chromosome aneuploidy, in contrast with near-
ly half of BubR1H/L1002P and BubR1H/H MEFs (Figure 8B). In all 
3 mutants, most aneuploidy resulted from chromosome gains 
(Figure 8, C and D). BubR1H/X753 MEFs not only had the highest 
aneuploidy incidence, but also much more complex aneuploid-
ization than BubR1H/L1002P and BubR1H/H MEFs, as evidenced by 
the increased number of chromosomes impacted per cell (Fig-
ure 8, E and F, and Supplemental Figure 9C). Furthermore, in all 
3 mutants, numerical changes occurred across a broad spectrum 
of chromosomes with little repetition (Supplemental Figure 9, A 
and B). Only BubR1H/X753 MEFs had a few chromosomes that were 
more frequently gained, including chromosomes 2, 6, 8, and 10 
(Supplemental Figure 9A). Chromosome losses were infrequent in 
BubR1H/H MEFs compared with BubR1H/X753 and BubR1H/L1002P MEFs 
(Supplemental Figure 9B). No increases in structural or segmen-
tal aneuploidy were observed in any of the biallelic MVA mutant 
MEFs compared to BubR1+/+ MEFs (Supplemental Figure 9, D and 
E). Collectively, these data indicate that early postnatal lethal-
ity, as observed in BubR1H/X753 mice, does seem to correlate with 
increases in both the rate and complexity of aneuploidization.
Consistent with the similarity in aneuploidy phenotypes, 
BubR1H/L1002P and BubR1H/H MEFs had the same chromosome 
missegregation rates, even though the prevalence of the actual 
types of segregation errors differed to some extent (Figure 8G). 
SAC activity was severely compromised in both BubR1H/L1002P and 
BubR1H/H MEFs (Figure 8H), as was BUBR1 accumulation at unat-
tached kinetochores at the onset of mitosis (Supplemental Figure 
10, A and B). Similar to the high increase in aneuploidy observed in 
BubR1H/X753 MEFs, these cells also exhibited significantly higher rates 
of chromosome missegregation compared with BubR1H/L1002P and 
BubR1H/L1002P and BubR1H/H mice model MVA syndrome het-
erogeneity. We sought to further explore the extent to which 
BubR1H/L1002P and BubR1H/H mice are subject to phenotypic hetero-
geneity, a hallmark of MVA syndrome. To this end, we focused on 
a series of progeroid phenotypes that characterize BubR1H/H mice, 
most of which represent MVA-associated pathologies. We discov-
ered that BubR1H/L1002P mice are highly sensitive to cataract forma-
tion, the median onset of which was 161 days, which is nearly iden-
tical to that of BubR1H/H mice (median onset, 168 days; Figure 7A).
A second overt progeroid phenotype of BubR1H/H mice, 
kyphosis, also developed in BubR1H/L1002P mice, but with delayed 
latency compared with BubR1H/H mice (median onset, 238 days 
versus 175 days; Figure 7B). In BubR1H/H mice, this phenotype is 
linked to a number of features of sarcopenia, including reduced 
grip strength, muscle fiber atrophy, and reduced work output 
during treadmill exercise (Figure 7, C–E, and Supplemental Fig-
ure 8, B and C). Importantly, these same features were observed 
in BubR1H/L1002P mice, although typically they were less severe 
in BubR1H/L1002P mice compared with BubR1H/H mice, which is in 
accordance with the delay in kyphosis onset.
Another key progeroid phenotype of BubR1H/H mice is fat tissue 
atrophy (lipodystrophy). Echo-MRI analysis on 8- to 10-month-
old mice indicated that this phenotype was fully recapitulated 
in BubR1H/L1002P mice (Figure 7F), which we confirmed by subse-
quent weighing of individual subcutaneous and visceral fat depots 
(Supplemental Figure 8D). Furthermore, the average size of fat 
cells was markedly reduced in BubR1H/L1002P mice (Figure 7G). The 
extent of the size reduction was similar to BubR1H/H mice.
Loss of cardiac stress tolerance is a hallmark of aging and has 
previously been linked to decreasing BUBR1 levels with aging (14). 
In accordance with this, cardiac stress tolerance of BubR1H/H mice is 
very low and is thought to be the primary cause of premature death 
in this model. To determine whether cardiac stress tolerance might 
be reduced in BubR1H/L1002P mice, and if so, whether the magnitude 
of the decline might correlate with the extent of lifespan shorten-
ing, we performed an isoproterenol challenge test. In this assay, 
which does not impact survival of BubR1+/+ mice, we intraperito-
neally injected a low dose of the β-adrenergic drug isoproterenol 
twice a day for 4 weeks (13). As expected, BubR1H/H mice were high-
ly sensitive to repeated isoproterenol administration, with half of 
the animals dying within 5 injections (Figure 7H). Lethality was 
also observed in BubR1H/L1002P mice, but to a lesser extent, as 50% 
of the animals expired after 18 injections and some of the remain-
ing mice showed no overt susceptibility. These data strengthen the 
idea that reduced tolerance to cardiac stress is a key determinant of 
lifespan shortening in biallelic BubR1 MVA syndrome models. Col-
lectively, these data indicate that phenotypic heterogeneity occurs 
despite similarity in overall BUBR1 protein level and that some phe-
notypes are more prone to divergency than others.
Progeroid heterogeneity occurs despite mitotic phenotype similar-
ity. The random reshuffling of chromosomes in multiple tissues 
is a common feature of MVA syndrome patients, irrespective of 
whether they have mutations in BUBR1, CEP57, or TRIP13 (1–4). 
However, whether and how the clinical heterogeneity that charac-
terizes MVA syndrome might be driven by heterogeneity of mitot-
ic defects has been difficult to assess, primarily because of the 
rarity of the syndrome and the limited availability of patient sam-
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likely driven by a combination of defects, including reduced SAC 
activity, defective attachment error correction, and aberrations in 
centrosome movement and spindle symmetry, with the higher level 
of aneuploidy in BubR1H/X753 MEFs probably due to more defective 
attachment error correction machinery.
Aneuploidy rates in mitotic splenocytes from 5-month-old 
BubR1H/L1002P and BubR1H/H mice were also markedly elevated, but 
unlike MEFs, to different degrees (38% and 15%, respectively) 
(Figure 9A, Supplemental Table 4, and ref. 8). The same was true 
for rates of PCS (Figure 9A). FISH analysis for chromosomes 4 and 
7 showed that rates of karyotypic abnormalities were prominently 
increased in a broad spectrum of tissues from both BubR1H/L1002P 
and BubR1H/H mice, with minimal differences observed between 
the 2 genotypes (Figure 9B and Supplemental Table 3). However, 
BubR1H/H MEFs, although SAC activity was similarly impaired in all 
3 mutants (Figure 8, G and H). However, error correction was more 
severely compromised in BubR1H/X753 MEFs than in BubR1H/L1002P 
and BubR1H/H MEFs (Figure 8I), providing a plausible explanation 
for their higher rates of chromosome misalignment and lagging. As 
for monoallelic MVA mutants, biallelic mutants also had impaired 
centrosome movement and formed non-perpendicular spindles at 
increased rates, although there was no distinction in the severity of 
these phenotypes among the 3 biallelic mutants (Figure 8, J and K). 
Since BubR1H/H MEFs also exhibited a significant increase in chro-
matin bridges, we assessed DNA damage by performing IF for the 
double-strand break (DSB) protein, 53BP1. However, we did not 
observe a significant increase in DSBs in any of the mutants (Figure 
8L). Thus, chromosome missegregation in biallelic MVA mutants is 
Figure 8. Phenotypically diverse MVA models have similar mitotic defects. (A) Incidence of aneuploidy and PCS in mitotically arrested passage-5 MEFs. 
BubR1H/H values are as previously reported (8). (B–F) Numerical aneuploidy assessments by single-cell DNA sequencing of the indicated passage-5 MEFs. 
Each n is as indicated in B. (G) Chromosome segregation errors in passage-5 MEFs assessed by live-cell imaging of MEFs expressing H2B-mRFP. (H) 
Colcemid-challenge assay on passage-5 MEFs measuring SAC activity. (I) Error correction in the indicated passage-5 MEFs assessed by monastrol wash-
out assay. (J and K) Incidence of slow centrosome movement (J) and non-perpendicular spindles (K) in the indicated passage-5 MEFs. (L) Percentage of 
passage-5 MEFs with DNA damage, as determined by the presence of 53BP1 foci. Each n indicates independent MEF lines. BubR1+/+ controls in H and J are 
as shown in Figure 3, C and E. Data are presented as mean ± SD (A) and mean ± SEM (B–L), and dots represent individual samples. Statistical significance 
was determined using 1-way ANOVA with the Holm-Šídák post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001. NS, not significant.
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ity, similar to BubR1H/H mice (Figure 10A, and data not shown). 
To obtain further evidence for accumulation of senescent cells 
in BubR1H/L1002P and BubR1H/H fat tissue, we conducted an unbi-
ased screen for senescence markers and components comprising 
the senescence-associated secretory phenotype (SASP) using a 
transcriptomics approach. To this end, RNA was collected from 
inguinal adipose tissue (IAT) from 8- to 10-month-old BubR1H/H, 
BubR1H/L1002P, and BubR1+/+ mice, and was used for RNA sequenc-
ing. Although BubR1H/H and BubR1H/L1002P IAT had several thou-
sand DEGs when compared with IAT of BubR1+/+ mice, only 16 
DEGs were observed when BubR1H/H and BubR1H/L1002P transcrip-
tomes were compared to each other (Figure 10B), indicating that 
similar biological aberrations occur in fat tissue of the 2 MVA mod-
els. Further, evaluation of the expression of the Cdkn2a locus, a 
well-established marker of cellular senescence and key driver of 
senescence in BubR1H/H mice (9, 10), revealed similarly elevated 
levels in both BubR1H/L1002P and BubR1H/H fat tissue (Figure 10B). 
To further evaluate the senescent-cell signature in these 2 models, 
we interrogated our lists of upregulated DEGs for putative SASP 
factors by evaluating the presence of genes encoding extracellu-
lar proteins (30). One hundred ninety of the DEGs observed in the 
IAT between MVA models and wild-type mice encode extracel-
lular proteins, many of which comprised known SASP functions, 
including proinflammatory factors, growth factors, regulators of 
extracellular protease activity, and other signaling factors (Fig-
ure 10C), supporting the idea that senescent cells with a bioac-
tive secretome accumulate in fat tissue of MVA models. Next, we 
focused on senescence in skeletal muscle. In contrast with fat, 
aneuploidy rate or degree alone does not clearly correlate with the 
severity of the progeroid phenotypes observed in BubR1H/L1002P and 
BubR1H/H MVA models, implying that other pathological events 
are key contributors or drivers.
Senescence-driven progeroid mechanisms are conserved in MVA 
models. Cellular senescence contributes to the development of 
certain progeroid phenotypes in BubR1H/H mice, including sar-
copenia, lipodystrophy, and cataract formation (9, 10). Although 
the senescence-inducing stressors in this model remain elusive, 
aneuploidy alone does not seem to be sufficient to activate this cell 
fate program. This is largely based on the observation that several 
CIN models involving genes other than BubR1 are not senescence 
prone, despite similar or higher rates of aneuploidization than 
reported for the BubR1H/H model (27). However, 2 recent studies 
have suggested that aneuploidy can drive senescence, at least in 
vitro (28, 29). In one of these studies, loss of SMC1, a component 
of the mitotic cohesin complex, was associated with induction of 
both cellular senescence and PCS, but no perturbations in SMC1 
were detected in senescence-prone BubR1H/H MEFs (Supplemen-
tal Figure 10C). However, in addition to the rate of aneuploid-
ization, the possibility that karyotype complexity is an important 
determining factor in cell fate determination in the various CIN 
models cannot be excluded and requires additional studies.
To further delineate the role of senescence in MVA syndrome 
pathologies, we sought to determine whether senescence also 
drives progeria in BubR1H/L1002P mice. Indeed, subcutaneous and 
visceral fat depots of BubR1H/L1002P mice stained for senescence- 
associated β-galactosidase (SA-β-gal) exhibited increased activ-
Figure 9. Progeroid MVA models exhibit severe mosaic aneuploidy. (A) Incidence of aneuploidy and PCS in mitotic splenocytes of 5-month-old mice. 
Images are representative of normal spreads and spreads with PCS. BubR1H/H values are as previously reported (8). BubR1+/+ controls are as shown in Figure 
4A. (B) Incidence of aneuploidy in tissues from 8- to 10-month-old mice assessed by FISH for chromosomes 4 and 7. Representative images shown. Scale 
bar: 2 μm. Each n indicates tissues from independent mice. Data are presented as mean ± SD (A) and mean ± SEM (B), and dots represent individual 
samples. Statistical significance was determined using 1-way ANOVA with the Holm-Šídák post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001. NS, not 
significant. SkM, skeletal muscle.
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sion was also significantly increased in both mutants (Figure 
10D), and a substantial proportion of the upregulated DEGs also 
encoded putative SASP factors (Figure 10E). Although there was 
some overlap between putative SASP factors of BubR1H/L1002P and 
BubR1H/H and BubR1H/L1002P gastrocnemius had only a few hun-
dred DEGs compared with wild-type, and a higher percentage of 
DEGs was identified between the 2 mutants (Figure 10D). How-
ever, in accordance with increased senescence, Cdkn2a expres-
Figure 10. Senescence-mediated pathologies are conserved among MVA models. (A) Images of SA-β-gal activity in adipose tissue (perirenal and IAT) 
from the indicated 8- to 10-month-old mice. (B) Venn diagrams of significantly DEGs from RNA sequencing analyses of 8- to 10-month-old fat (IAT) from 
the indicated mice (left).↑, upregulated genes; ↓, downregulated genes. Heatmap of expression (row Z-scores) of cell cycle inhibitors p16/p19 (Cdkn2a) 
in each of the individual samples (right). n = 4 independent mice/genotype were used for analyses. FC, fold change. (C) Venn diagrams of putative SASP 
factors within the upregulated DEGs from BubR1H/L1002P versus BubR1+/+ and BubR1H/H versus BubR1+/+ RNA sequencing results from fat, determined by 
overlap with a gene ontology (GO) GO:0005615 “Extracellular Space” gene list (top). Heatmap of expression of 53 select putative SASP factors significantly 
upregulated in BubR1H/L1002P and/or BubR1H/H fat (bottom). Gene names in bold text denote established SASP factors. Arrowheads indicate putative SASP 
factors present in fat and skeletal muscle. (D) Venn diagrams of significantly DEGs from RNA sequencing analyses of 8- to 10-month-old gastrocnemius 
skeletal muscle from the indicated mice (left), as above in B. Heatmap of expression (row Z-scores) of cell cycle inhibitors p16/p19 (Cdkn2a) in each of the 
individual samples (right), as above in B. n = 4 BubR1+/+ and BubR1H/L1002P, and n = 3 BubR1H/H mice were used for analyses. (E) Venn diagrams of putative 
SASP factors within the upregulated DEGs from BubR1H/L1002P versus BubR1+/+ and BubR1H/H versus BubR1+/+ RNA sequencing results from skeletal muscle, 
as above in C (top). Heatmap of expression of 26 select putative SASP factors significantly upregulated in BubR1H/L1002P and/or BubR1H/H skeletal muscle, as 
above in C (bottom). See Methods for statistical analyses for RNA sequencing (B and D). **P < 0.01; ***P < 0.001. NS, not significant.
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that increased tumor cell proliferation contributes to the observed 
reduction in tumor latency. BubR1+/L1002P and BubR1+/– mice also 
exhibit an increase in lung tumor size when challenged with DMBA, 
reminiscent of that previously reported for BubR1+/X753 mice (21), 
but whether this is due to accelerated tumor initiation or prolifer-
ation, or both, remains to be established. BubR1+/X753 mice, but not 
BubR1+/L1002P and BubR1+/– mice, develop multiple progeroid pheno-
types observed in BubR1H/H mice, which establish themselves in the 
second year of life, including sarcopenia, lipodystrophy, and cata-
ract formation (21). In probing the mechanism associated with these 
phenotypes, we found that skeletal muscle from BubR1+/X753 mice is 
characterized by hyperactive mTORC1 signaling. Chronic hyper-
activation of mTORC1 has been linked to skeletal muscle atrophy 
and induction of cellular senescence (33, 34). This, combined with 
studies demonstrating that inhibition of mTOR with rapamycin 
slows age-related deterioration in mice (26), suggests that hyperac-
tive mTORC1 signaling may be a driver of accelerated sarcopenia 
in BubR1+/X753 mice. BUBR1 and MAD2 have recently been impli-
cated in the control of insulin signaling and metabolic homeostasis, 
raising the interesting possibility that disruption of this function is 
linked to uncontrolled mTORC1 activity (20). Collectively, these 
data reveal that a key feature of MVA syndrome patients, phenotyp-
ic heterogeneity, is conserved among mouse models for heterozy-
gous BUBR1 MVA allele carriers (Supplemental Table 5).
Third, although we failed to model the MVA patient 
BUBR1L1012P/X753, we successfully created a viable MVA syndrome 
model using BUBR1 mutations found in MVA patients. Previously, 
modeling was restricted to the use of hypomorphic BubR1 alleles, 
mimicking a BUBR1 variant found in Asian MVA patients that have 
no discernable mutations, but nevertheless yield low amounts 
of wild-type BUBR1 protein (1). However, only 1 BUBR1 MVA 
patient with 2 hypomorphic alleles has been reported to date (35). 
Although this has raised questions about the faithfulness of the 
model, its usefulness became more accepted with the discovery 
that the critical contribution of many missense mutations found 
in MVA syndrome patients is destabilization of the BUBR1 pro-
tein and lowering overall protein amounts (7). On the other hand, 
an independently generated hypomorphic model, referred to as 
BubR1L/L, did not show any of the overtly detectable progeroid 
features of BubR1H/H mice, such as kyphosis, lipodystrophy, and 
cataract formation (36), suggesting that subtle allelic effects may 
have dramatic phenotypic consequences. This idea is underscored 
here by the observation that BubR1H/H and BubR1H/L1002P mice have 
quite obvious phenotypic differences despite an inability to detect 
differences in overall BUBR1 protein levels in a broad spectrum 
of tissues. The mere difference between total BUBR1 protein lev-
els in BubR1H/H and BubR1H/L1002P mice is that in the latter strain 
the total pool consists of a mixture of BUBR1WT and BUBR1L1002P 
protein rather than BUBR1WT alone. Although several pheno-
types of BubR1H/L1002P are similar in severity to those of BubR1H/H 
mice, including lipodystrophy, cataractogenesis, and carcinogen- 
induced tumor susceptibility, others are definitely milder, includ-
ing growth retardation, cardiac stress sensitivity, lifespan short-
ening, and muscle wasting. These findings are important in that 
they reveal that seemingly subtle allelic effects can be the cause 
of rather remarkable phenotypic heterogeneity, a key hallmark of 
MVA syndrome (Supplemental Table 5).
BubR1H/H muscles, BubR1H/H muscles contained a relatively large 
number of unique SASP factors, consistent with a more severe 
degenerative phenotype (Figure 10E). Taken together, these find-
ings indicate that progeroid mechanisms in select BubR1H/H tissues 
are mediated by the accumulation of senescent cells, which is pre-
served in BubR1H/L1002P mice. Furthermore, diversity in senescent 
cell properties (SASP composition) may underlie the difference in 
the severity of the progeroid skeletal muscle phenotypes between 
BubR1H/L1002P and BubR1H/H mice.
Discussion
Studies of rare genetic diseases are important in that they often 
provide entry points for understanding cellular and organismal 
mechanisms that underlie more common degenerative and patho-
logical processes, including cancer, aging, and age-related dis-
eases (31). To learn more about the mechanisms underlying MVA 
syndrome and its phenotypic heterogeneity, we sought to mimic 
human BUBR1 MVA mutations in mice and characterize the phe-
notypic consequences (summarized in Supplemental Table 5). 
Here, our use of 4 such mutations in various combinations, with 
each other or in combination with a BubR1+ allele, unearthed sev-
eral important insights into BUBR1 and its role in MVA progeria 
syndrome, including a better understanding of how the BUBR1 
allelic effects drive pathological heterogeneity among patients.
First, our study uncovers that it is difficult to create mouse 
models for BUBR1 MVA syndrome patients. We show that a com-
bination of BUBR1 mutations that is compatible with postnatal 
viability in humans causes death during early embryogenesis in 
mice, most likely due to mitotic failure around the time of embryo 
implantation, reminiscent of mice lacking the BUBR1 binding 
partner BUB3 (22). A recent effort to model an MVA patient with 
a biallelic nonsense mutation in CEP57 supports the notion that 
the tolerance for MVA-associated mutations is lower in mice than 
in humans (6). It should be noted, however, that the BUBR1 MVA 
patient that our mouse model mimicked was very short-lived and 
died at 3.6 months of age with a broad spectrum of pathologies (2), 
raising the possibility that future modeling of MVA patients with 
longer lifespans and less severe pathologies could be more success-
ful. On the other hand, the CEP57 patient that we recently modeled 
died substantially later, at 15 years of age (3), yet the correspond-
ing mice still died as newborns (6). BubR1–/H and BubR1H/X753 mice 
also die shortly after birth. All these strains share the commonality 
that aneuploidy rates are relatively high. Since aneuploidy has been 
associated with reduced cellular fitness, impaired proteostasis, and 
engagement of stress response pathways (32), it is plausible that 
organ failure is inevitable above a certain threshold rate of mosaic 
aneuploidization (Supplemental Table 5).
Second, by comprehensively analyzing the BubR1+/L1002P and 
BubR1+/– mouse strains, each modeling a distinct BUBR1 MVA muta-
tion, we uncovered that carrying these heterozygous mutations 
is not inconsequential, but instead is associated with select MVA- 
related pathologies that tend to be relatively mild and typically man-
ifest themselves only in the second year of life. The BubR1+/L1002P and 
BubR1+/– strains both exhibit a reduction in median lifespan, pre-
sumably due to reduced tumor latency. The mitotic index of lym-
phomas of both these mutants is significantly increased (Figure 2E) 
compared with lymphomas of wild-type control mice, suggesting 
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ingly clear that the bioactive secretome of senescent cells is an 
important driver of tissue degeneration, but a comprehensive 
assessment of the SASP in the context of MVA syndrome has not 
been conducted. Here, using an RNA sequencing approach, we 
identified a broad spectrum of putative SASP factors implicated in 
senescent cell–dependent degeneration in fat and skeletal muscle. 
These findings suggest that there is substantially more heteroge-
neity in bioactive secretomes in vivo than expected based on initial 
in vitro data (41). Further, we uncovered that the number of puta-
tive SASP factors is different in fat and skeletal muscle irrespective 
of the MVA syndrome–causing BubR1 alleles, with fat from both 
BubR1H/H and BubR1H/L1002P mice showing a rather large number 
of factors compared with muscle. Importantly, rates of senes-
cence are similar between BubR1H/H and BubR1H/L1002P mice based 
on levels of Cdkn2a expression. This holds true for both fat and 
skeletal muscle. For fat this is perhaps not surprising because lipo-
dystrophy severity is similar between BubR1H/H and BubR1H/L1002P 
mice, and their SASP factors are highly conserved. In the case of 
skeletal muscle, however, BubR1H/H mice exhibit more severe tis-
sue wasting than BubR1H/L1002P mice. Because BubR1H/H muscles 
seem to have a more complex secretome than their BubR1H/L1002P 
counterparts, one plausible explanation would be that senescent 
cells that accumulate in BubR1H/H muscles have more profound 
degenerative properties. This may be due to differences in senes-
cence-inducing stressors in these mice due to allelic effects, or dif-
ferential evolution of cells once they enter the senescent state, as 
previously suggested (42). However, the possibility that degener-
ative mechanisms beyond senescence may also contribute to the 
muscle pathology in BubR1H/H mice cannot be excluded.
In conclusion, the use of mice mimicking BUBR1 MVA muta-
tions has unearthed many insights regarding the physiological 
relevance of BUBR1, and its role in MVA progeria syndrome. 
The results of our study predict that future modeling of other 
MVA mutations is likely to uncover important new clues about 
BUBR1-mediated biological processes in cancer, aging, and 
age-related diseases. Additionally, it will be imperative to estab-
lish mutant mouse models designed to identify the senescence-in-
ducing stressors activated by BUBR1 dysfunction. Likewise, it will 
be important to establish mouse models that further probe the 
in vivo relevance of the recently discovered non-mitotic BUBR1 
functions in receptor signaling, and control of CDC20-activated 
APC/C substrate stability (20, 43, 44).
Methods
Mouse strains. BubR1+/L1002P mice were generated by converting the 
first thymidine of BubR1 codon 1002 into a cytosine (CTT>CCT) 
using previously described gene targeting in mouse embryonic stem 
(ES) cells (21). See the Supplemental Figure 1 legend for details. The 
BubR1+/X753, BubR1+/–, and BubR1+/H mice used herein have been pre-
viously described (8, 21). All mice used in this study were on a mixed 
129/Sv × C57BL/6 background, and were housed in a pathogen- 
free barrier facility.
MEF generation and culture. MEFs were generated as previously 
described (22). Primary MEFs were cultured and frozen at passages 
2 and 3, and vials thawed and used for experiments between passages 
4 and 6. At least 3 independent MEF lines were used for each experi-
ment, unless otherwise noted.
Fourth, although our study does not fully resolve key long-
standing questions as to how changes in BUBR1 drive a broad spec-
trum of highly complex pathologies, it does provide several import-
ant mechanistic insights. For instance, although BUBR1 levels do 
not closely track with phenotypic severity, this study identifies 
several critical BUBR1 thresholds in vivo. A reduction of approxi-
mately 40%–90% in BUBR1 protein levels results in tumor predis-
position or mild premature-aging phenotypes, whereas a reduction 
of greater than 90% results in progeroid phenotypes or early post-
natal lethality (Supplemental Table 5). The BubR1X753/L1002P model 
does not fit this scheme, however, and suggests that there are other 
factors driving early embryonic lethality in this case, such as exten-
sive aneuploidization. Since aneuploidy rates also increase as these 
critical BUBR1 thresholds are breached, it is difficult to rule this out 
as a contributing factor. However, it is unlikely that differences in 
aneuploidization represent a major source of phenotypic hetero-
geneity between the BubR1H/H and BubR1H/L1002P models given that 
their mitotic phenotypes show remarkable similarity with regard 
to levels of SAC, error correction, and spindle geometry impair-
ment, rates of chromosome missegregation, and aneuploidization 
in MEFs. Moreover, although aneuploidy rates in mitotically active 
splenocytes are substantially higher in the BubR1H/L1002P model, 
FISH-based assessments point to similar amounts of chromo-
some mosaicism in a wide spectrum of tissues of both BubR1H/H 
and BubR1H/L1002P mice. Importantly, a recent study illustrated that 
chromosome segregation fidelity outside the normal tissue archi-
tecture is severely compromised, and that in vitro culture of cells on 
monolayers promotes aneuploidization (37). In light of these find-
ings, aneuploidy data from cultured MEFs are unlikely to reflect 
in vivo aneuploidy rates. However, our method for assessment of 
aneuploidy in splenocytes is not subject to this caveat, as it does 
not involve any cells engaging in chromosome segregation while in 
culture. Since this method focuses only on a subset of splenocytes, 
namely those that are mitotically active, rates obtained are unlikely 
to faithfully reflect aneuploidy rates in the spleen at large. There-
fore, the rates of aneuploidy obtained by FISH probably represent 
the most reliable relative measure for aneuploidy between the 2 
MVA models. Moreover, FISH has been shown to be consistent 
with assessments of aneuploidy by whole-genome sequencing, 
underscoring its validity as a measure of aneuploidy (38). Another 
indication that aneuploidy alone is not a prominent source for phe-
notypic heterogeneity is that the progeroid phenotypes associated 
with BubR1 mutations are typically not observed in the now large 
collection of mouse strains with mutations in other key mitotic reg-
ulators (27, 39, 40). This even includes mutants involving promi-
nent binding partners or closely related BUBR1 family members, 
such as BUB3, BUB1, MAD2, and CDC20.
Cellular senescence is one mechanism that has been causal-
ly linked to the induction of a subset of progeroid phenotypes in 
BubR1H/H mice, including sarcopenia, cataracts, and lipodystrophy 
(8, 10), but how BUBR1 aberration induces cellular senescence 
remains to be determined. However, our side-by-side compar-
ison of the BubR1H/H and BubR1H/L1002P models provides import-
ant information regarding the relationship between BUBR1 and 
cellular senescence. First, we demonstrate that there is a strong 
conservation of senescence-dependent phenotypes between the 
2 independent models. Over recent years, it has become increas-
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Analysis of age-related phenotypes. Mouse cohorts for lifespan 
and healthspan studies were generated, and animals were evaluated 
biweekly for cataracts and kyphosis as previously described (9). For 
evaluation of survival and cancer deaths, moribund mice were eutha-
nized and all major organs were screened grossly for overt tumors, as 
previously described (9). Exercise ability by treadmill testing was per-
formed and work output was calculated as previously described (10). 
Forelimb grip strength testing was performed as previously described 
(49). Body composition and total body fat were determined using an 
EchoMRI-100 QNMR instrument (Echo Medical Systems), as previ-
ously described (49). Total body lean and fat mass were recorded, and 
total body fat percentages were determined by dividing fat mass by 
body mass. Bone mineral density (BMD) was determined with dual- 
energy x-ray absorptiometry scanning (Lunar PIXImus densitometer), 
as previously described (49). Cardiac stress tolerance was assessed 
using a chronic isoproterenol test, similarly to previously described 
studies (13). Terminal healthspan analyses of fat depot weights and 
collection of fat and skeletal muscle were performed as previously 
described (8, 9). Fat depot weights were normalized to the length of 
the right femur. Skeletal muscle (gastrocnemius) and fat (IAT) were 
fixed in 10% normal buffered formalin, embedded in paraffin, and 
5-μm sections were stained with hematoxylin and eosin (H&E) as 
previously described (9). Skeletal muscle (gastrocnemius) fiber and 
fat (IAT) adipocyte sizes were determined as previously described (9), 
with the following modifications: cross-sectional area measurements 
of 150 fibers or adipocytes were made using ImageJ software. The 
mean of these measurements was then obtained per sample, and indi-
vidual means were then averaged per group.
Tumor analyses. For spontaneous tumor analyses, mice were main-
tained until 18–20 months of age, and were then euthanized and grossly 
examined for overt tumors in all major organs, as described above. Car-
cinogen-induced tumorigenesis studies were performed with admin-
istration of DMBA as previously described (45). We note that studies 
on BubR1+/L1002P and BubR1+/– cohorts were conducted several years 
apart and with different batches of DMBA, and that variation between 
experiments can be observed (~20%–55% lung tumor incidence, and 
~0.65–2.2 average tumor numbers in wild-type mice). Animals were 
euthanized at 4 months of age, and screened for the presence of overt 
tumors, including skin and lung. All tumors were counted, and the lon-
gest diameter measured at the time of collection or from images taken 
at time of collection. Lung tumor volumes were calculated using diam-
eter measurements as previously described (21). To assess the mitotic 
index of spontaneous lymphatic tumors, mitotic cells were visualized 
by IF labeling of 2 paraffin sections separated by 150 μm for pHH3 
(EMD Millipore, catalog 06-570) as previously described (6, 47).
SA-β-gal staining. Whole-mount SA-β-gal staining on fat (IAT) was 
performed as previously described (13). At least 3 animals were analyzed.
RNA library preparation, sequencing, and bioinformatic analyses. 
RNA was extracted from fat tissue or gastrocnemius muscle from 8- 
to 10-month-old mice using the RNeasy lipid and fibrous tissue kits, 
respectively (Qiagen, catalog 74704 and 1023539), and from gastroc-
nemius muscles from 3-month-old mice using the RNeasy fibrous 
tissue kit: n = 4 BubR1+/+, BubR1H/L1002P, and BubR1H/H mice for IAT; 
n = 4 BubR1+/+ and BubR1H/L1002P mice and n = 3 for BubR1H/H mice for 
8- to 10-month-old gastrocnemius; and n = 3 BubR1+/+, BubR1+/L1002P, 
and BubR1+/X753 mice for 3-month-old gastrocnemius. Library prepa-
ration and RNA sequencing were performed as previously described 
Western blotting and quantifications. Western blot analyses were 
performed as previously described (8). MEF and tissue lysates were 
prepared as previously described (14). For assessments of BUBR1 sta-
bility, passage-5 MEFs were treated with cycloheximide, MG132, or 
the combination for 5 hours, as previously described (7). The mouse 
anti-BUBR1 (BD Transduction, catalog 612503), rabbit anti–α-tubulin 
(Cell Signaling Technology, catalog 2125), rabbit anti–phospho-p70 S6 
kinase (Thr389; Cell Signaling Technology, catalog 9208), and rabbit 
anti–phospho-4EBP1 (Thr37/46; Cell Signaling Technology, catalog 
2855) primary antibodies were used at a dilution of 1:1,000. PonS 
staining (1.1 g/mL Ponceau S (Sigma-Aldrich) in 1% glacial acetic acid) 
served as a loading control unless otherwise noted. BUBR1 levels were 
quantified using ImageJ software (NIH) and were normalized to levels 
of α-tubulin or total protein using PonS.
Quantitative reverse transcriptase PCR. Total RNA was extract-
ed from passage-5 MEFs using the RNeasy mini kit (Qiagen, catalog 
74104). cDNA synthesis and qRT-PCR were performed as previously 
described (45). See the Supplemental Figure 2 legend for details.
Karyotyping and interphase FISH. Chromosome counts of meta-
phase spreads from MEFs and mouse splenocytes were performed at 
passage-5 and 5 months of age, respectively, as previously described 
(22). Fifty spreads were analyzed per sample. Interphase FISH using 
probes for mouse chromosomes 4Eq2 and 7qA1 were performed on 
single-cell suspensions generated from MEFs and various mouse tis-
sues as previously described (14). One hundred interphase cells were 
analyzed per sample. Karyotype analysis by single-cell DNA sequenc-
ing was performed on passage-5 MEFs as previously described (46, 47). 
At least 3 independent MEF lines were sequenced per genotype, and 
19–24 cells were sequenced per line. Whole chromosomal and struc-
tural aneuploidies were determined using AneuFinder software (46).
IF and mitotic assays. Indirect IF was performed and quantified 
using ImageJ software as previously described (45). Assessments of 
BUBR1 (BD Transduction, catalog 612503) and SMC1 (Abcam, catalog 
ab133643) centromere localization (Antibodies, Inc., catalog 15-234-
001) (15); centrosome movement (anti–γ- and α-tubulin; Sigma-Aldrich, 
catalog T5192 and T9026) and spindle geometry (anti–γ-tubulin and 
–phospho–histone H3 [Ser10, pHH3]; Sigma-Aldrich, catalog T6557 and 
EMD Millipore, catalog 06-570) (45); and DNA damage (anti-53BP1, 
Novus Biologicals, catalog NB100-305) (48) were performed as previ-
ously described. A laser-scanning microscope (LSM 880; Carl Zeiss) 
with an inverted microscope (Axiovert 100M; Carl Zeiss) was used for 
imaging. The monastrol washout assay was performed as previously 
described (15). Briefly, 100 μM monastrol (Enzo Life Sciences, catalog 
BML-GR322) was added to passage-5 MEFs for 60 minutes, followed 
by the addition of 10 μM MG132 (Sigma-Aldrich, catalog C2211) plus 
monastrol for an additional 60 minutes. Cells were then released in 10 
μM MG132 alone for 90 minutes and fixed in 4% paraformaldehyde for 
10 minutes and stained with Hoechst. Metaphase cells with 1 or more 
misaligned chromosomes were scored as containing uncorrected mis-
alignments. At least 3 independent MEF lines per genotype were used 
for analyses, and at least 25 metaphase cells were analyzed per line.
Live-cell imaging analyses. Chromosome segregation analyses and 
colcemid challenge assays were performed on passage 5–6 prima-
ry MEFs stably expressing H2B-mRFP, as previously described (15). 
Colcemid was added at 0.5 μg/mL (Karyomax, Gibco, catalog 15210-
040). At least 23 and 10 cells per line were analyzed for chromosome 
segregation and colcemid challenge assays, respectively.
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studies were chosen based on previously published studies in which 
differences were observed. The experiments were not randomized, 
and the investigators were not blinded.
Study approval. All animal procedures were reviewed and approved 
by the Institutional Animal Care and Use Committee (IACUC) at the 
Mayo Clinic, Rochester, Minnesota (protocol A00002189).
Data availability. RNA sequencing and single-cell DNA sequenc-
ing data have been deposited into the National Center for Biotech-
nology Information’s Gene Expression Omnibus under the accession 
numbers GSE134781 (3-month-old monoallelic skeletal muscle data) 
and GSE134780 (8- to 10-month-old biallelic skeletal muscle and fat 
data) and into the European Nucleotide Archive under the accession 
number PRJEB33810.
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(47). Fastq files of paired-end reads were aligned with Tophat 2.0.14 to 
the UCSC reference genome mm10 using Bowtie2 2.2.6 with default 
parameters. Differential expression analyses were performed using R 
package DESeq2 1.10.1 after removing genes with average raw counts 
less than 10 (47). Genes with lfcMLE (unshrunken maximum likeli-
hood estimate of log2 fold change produced by DESeq2) greater than 
0.45 or less than –0.45, and FDR less than 0.05 were considered sig-
nificantly differentially expressed. Functional enrichment analyses 
for DEGs from the 3-month-old monoallelic skeletal muscle sam-
ples was performed using the STRING database, version 11 (https://
string-db.org; ref. 25). Biological processes with FDR less than 0.05 
were considered significantly enriched, and were classified into func-
tional groups. For 8- to 10-month-old biallelic skeletal muscle and fat 
samples, putative SASP factor genes were extracted from the Gene 
Ontology Consortium (Mus musculus MGI), and QuickGO database 
for the annotation GO:0005615 “Extracellular Space” (30, 50, 51). 
Gene lists from both reference databases were merged, resulting in 
the identification of 1845 factors. SASP gene lists were then compared 
to differentially upregulated gene lists. Heatmaps were generated 
with Morpheus (Broad Institute; https://software.broadinstitute.org/ 
morpheus). For p16/p19 (Cdkn2a) expression heatmaps row Z-scores 
were used, and for putative SASP factor and mTORC1-related gene 
expression heatmaps lfcMLE values were used.
Statistics. Statistical significance was determined using the log-
rank test, 2-tailed Fisher’s exact test, 1-way ANOVA with a Holm-
Šídák post hoc test, 2-tailed unpaired t test, and Mann-Whitney U test 
as noted in the figure legends. For 1-way ANOVA with Holm-Šídák 
correction for multiple comparisons, all groups were compared, with 
the exception of Figure 2E; Figure 3, A–D; Supplemental Figure 2A; 
and Supplemental Figure 5 where groups were compared to wild-type 
controls only, and where select comparisons were made (Supplemen-
tal Figure 2, C and E) as noted in the legends. All tests were performed 
using GraphPad Prism software, except for the 2-tailed unpaired t test, 
which was performed using Microsoft Excel. A P value less than 0.05 
was considered statistically significant. Sample sizes for all animal 
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